Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests.
Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests.
复制标题
DOI：
10.1016/j.jinf.2013.03.015
复制
发表时间：
2013-08
期刊：
影响因子：
--
通讯作者：
Yuen KY
中科院分区：
文献类型：
--
作者：
Chan KH;Chan JF;Tse H;Chen H;Lau CC;Cai JP;Tsang AK;Xiao X;To KK;Lau SK;Woo PC;Zheng BJ;Wang M;Yuen KY
由新型β冠状病毒人冠状病毒EMC（HCoV-EMC）引起的严重急性呼吸综合征（SARS）样疾病最近出现。HCoV-EMC在遗传学上与Tylonycteris-bat-coronavirus-HKU 4和Pipistrellus-bat-coronavirus-HKU 5密切相关。我们对中国南方野生动物市场的94名野味动物处理人员、28名SARS患者和152名健康献血者的存档血清进行了血清阳性率研究，以评估HCoV-EMC和相关病毒侵入人类的人畜共患潜力和证据。采用间接免疫荧光（IF）筛查和中和抗体确证试验检测抗HCoV-EMC和抗SARS-CoV抗体。2名（2.1%）动物操作员抗HCoV-EMC和SARS-CoV的IF抗体滴度≥1：20，中和抗体滴度<1：10。没有献血者对这两种病毒有抗体。令人惊讶的是，17/28（60.7%）的SARS患者具有显著的IF抗体滴度，7/28（25%）具有低滴度的抗HCoV-EMC中和抗体，其与HCoV-OC 43的中和抗体显著相关。生物信息学分析表明，一个显着的B细胞表位重叠的刺突蛋白的七肽重复-2区域。SARS-CoV相对于其他β冠状病毒的毒力可能会增强针对其他β冠状病毒的交叉反应中和抗体。恢复期SARS血清可能含有针对其他β冠状病毒的交叉反应抗体，并混淆HCoV-EMC的血清阳性率研究。
A severe acute respiratory syndrome (SARS)-like disease due to a novel betacoronavirus, human coronavirus EMC (HCoV-EMC), has emerged recently. HCoV-EMC is phylogenetically closely related to Tylonycteris-bat-coronavirus-HKU4 and Pipistrellus-bat-coronavirus-HKU5 in Hong Kong. We conducted a seroprevalence study on archived sera from 94 game-food animal handlers at a wild life market, 28 SARS patients, and 152 healthy blood donors in Southern China to assess the zoonotic potential and evidence for intrusion of HCoV-EMC and related viruses into humans. Anti-HCoV-EMC and anti-SARS-CoV antibodies were detected using screening indirect immunofluorescence (IF) and confirmatory neutralizing antibody tests. Two (2.1%) animal handlers had IF antibody titer of ≥1:20 against both HCoV-EMC and SARS-CoV with neutralizing antibody titer of <1:10. No blood donor had antibody against either virus. Surprisingly, 17/28 (60.7%) of SARS patients had significant IF antibody titers with 7/28 (25%) having anti-HCoV-EMC neutralizing antibodies at low titers which significantly correlated with that of HCoV-OC43. Bioinformatics analysis demonstrated a significant B-cell epitope overlapping the heptad repeat-2 region of Spike protein. Virulence of SARS-CoV over other betacoronaviruses may boost cross-reactive neutralizing antibodies against other betacoronaviruses. Convalescent SARS sera may contain cross-reactive antibodies against other betacoronaviruses and confound seroprevalence study for HCoV-EMC.